ストックスクリーナーアプリを入手
27.61
1.32%
-0.305
前日終値:
$27.92
開ける：
$28.1
24時間の取引高:
5.38M
Relative Volume:
0.55
時価総額：
$10.74B
収益：
$3.14B
当期純損益:
$-3.36B
株価収益率:
-3.1632
EPS:
-8.73
ネットキャッシュフロー:
$-4.03B
1週間 パフォーマンス:
-2.89%
1か月 パフォーマンス:
+12.59%
6か月 パフォーマンス:
+3.30%
1年 パフォーマンス:
-53.19%
1日の値動き範囲:
$27.40
$28.30
1週間の範囲:
$26.91
$29.45
52週間の値動き範囲:
$23.15
$59.73
Moderna Inc Stock (MRNA) Company Profile
MRNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.61 | 10.86B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
414.79 | 107.98B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.41 | 59.07B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.10 | 59.76B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
803.40 | 49.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
335.35 | 38.56B | 4.56B | -176.77M | 225.30M | -1.7177 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
Is Moderna Inc. trending in predictive chart modelsRate Hike & Daily Stock Trend Reports - newser.com
Moderna, Inc. $MRNA Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
GSK Doesn't Have To Explain COVID Vax Claims For Moderna - Law360
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing - sharewise.com
Updated COVID shot led to less severe illness, fewer hospitalizations last year, US study finds - MarketScreener
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further? - ts2.tech
Moderna, Inc. (MRNA): Among the Best Vaccine Stocks to Buy According to Hedge Funds - MSN
Moderna (MRNA) COVID-19 Booster Recommendations Updated by CDC - GuruFocus
CDC adopts individual-based decision-making for COVID-19 shots (MRNA:NASDAQ) - Seeking Alpha
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna - WCIV
Moderna (MRNA): Assessing Valuation After Recent 12% Share Price Jump and Updated Financials - Yahoo Finance
Will Moderna Inc. see short term momentum2025 Year in Review & Fast Moving Stock Trade Plans - newser.com
Key metrics from Moderna Inc.’s quarterly data2025 EndofYear Setup & Step-by-Step Swing Trade Plans - newser.com
Day 5 of Gains Streak for Moderna Stock with 16% Return (vs. -31% YTD) [10/3/2025] - Trefis
Moderna Inc. (MRNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - Greenville Online
Moderna Says GSK ‘Abusing’ Patents to Siphon Covid Shot Profits - Bloomberg Law News
How to interpret RSI for Moderna Inc. stockMarket Risk Analysis & Smart Allocation Stock Reports - newser.com
What high frequency data says about Moderna Inc.Market Trend Review & Daily Stock Momentum Reports - newser.com
Moderna (MRNA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
The CDC still hasn't issued COVID vaccine guidelines, leaving access in limbo - NPR
What to know about this fall’s COVID-19 vaccine - The Globe and Mail
November 14th Options Now Available For Moderna (MRNA) - Nasdaq
6 Healthcare Stocks Positioned to Soar After Trump-Pfizer Deal - Investing.com
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency? - The Globe and Mail
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
Union Bancaire Privee UBP SA Sells 15,518 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Sold by Public Employees Retirement System of Ohio - MarketBeat
Brookline Reaffirms Price Target for Moderna (MRNA) After Strong mRNA-1283 Vaccine Results - Yahoo
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK - Detroit Free Press
Moderna Stock Is Rallying Wednesday: What's Driving The Action? - Benzinga
Moderna (NASDAQ:MRNA) Shares Up 5.9%Here's Why - MarketBeat
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Moderna (MRNA) Continues Upward Trend in Early Trading - GuruFocus
mRNA Vaccine and Therapeutics Market to Hit USD 127.8 Billion by 2034, Growing at 10.7% CAGR - openPR.com
Applying chart zones and confluence areas to Moderna Inc.Market Activity Summary & Low Risk High Win Rate Stock Picks - newser.com
Tools to assess Moderna Inc.’s risk profileGDP Growth & Pattern Based Trade Signal System - newser.com
Automated trading signals detected on Moderna Inc.IPO Watch & Weekly Watchlist for Hot Stocks - newser.com
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Online Athens
mRNA Market Forecasted to Reach USD 128.6 Billion by 2034, Key Players: Moderna & Pfizer/BioNTech - openPR.com
2 Beaten-Down Stocks to Buy and Hold for a Decade - Yahoo Finance
Chart based exit strategy for Moderna Inc.2025 Market WrapUp & Daily Price Action Insights - newser.com
Moderna, Inc. (MRNA) Stock Analysis: Navigating the 80.69% Potential Upside Amidst Challenges - DirectorsTalk Interviews
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 - The Daily Jeffersonian
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 - The Daily Jeffersonian
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
0.85%
1.17%
大文字化:
|
ボリューム (24 時間):